{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:21:56Z","timestamp":1768335716914,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vhri.2025.101091","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T21:35:46Z","timestamp":1739568946000},"page":"101091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece"],"prefix":"10.1016","volume":"46","author":[{"given":"Charalampos","family":"Tzanetakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Psarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Gourzoulidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vhri.2025.101091_bib1","first-page":"235","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"7","author":"Levine","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"12","key":"10.1016\/j.vhri.2025.101091_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A\u00a0comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis Mon"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2025.101091_bib3","article-title":"Trends in incidence of inflammatory bowel disease in northwest Greece","volume":"11","author":"Skamnelos","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"issue":"5","key":"10.1016\/j.vhri.2025.101091_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study","volume":"5","author":"Burisch","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.vhri.2025.101091_bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/03007995.2020.1771293","article-title":"Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population","volume":"36","author":"Pilon","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.vhri.2025.101091_bib7","first-page":"246","article-title":"Surgical principles in the treatment of ulcerative colitis","volume":"31","author":"Kuhn","year":"2015","journal-title":"Viszeralmedizin"},{"issue":"8","key":"10.1016\/j.vhri.2025.101091_bib8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/apt.13763","article-title":"Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis","volume":"44","author":"Peyrin-Biroulet","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.vhri.2025.101091_bib9","first-page":"447","article-title":"Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US","volume":"18","author":"Cohen","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.vhri.2025.101091_bib10","series-title":"Greek Therapeutic Protocol for Ulcerative Colitis","year":"2023"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.vhri.2025.101091_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284819848631","article-title":"Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience","volume":"12","author":"D\u2019Amico","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.vhri.2025.101091_bib13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/apt.13547","article-title":"Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis","volume":"43","author":"Kennedy","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.vhri.2025.101091_bib14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ecco-jcc\/jjz038","article-title":"The impact of raising the bar for clinical trials in ulcerative colitis","volume":"13","author":"Sands","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"issue":"10292","key":"10.1016\/j.vhri.2025.101091_bib15","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vhri.2025.101091_bib16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.vhri.2025.101091_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status","volume":"20","author":"Sandborn","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.vhri.2025.101091_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.vhri.2025.101091_bib20","first-page":"513","article-title":"Seidman EJTaig. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Kopylov","year":"2016"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib21","first-page":"1","article-title":"The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"20","author":"Armuzzi","year":"2020"},{"issue":"6","key":"10.1016\/j.vhri.2025.101091_bib22","first-page":"941","article-title":"Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the United States","volume":"26","author":"Long","year":"2020"},{"key":"10.1016\/j.vhri.2025.101091_bib24","series-title":"The ASCRS Manual of Colon and Rectal Surgery","article-title":"Surgical Management of Ulcerative Colitis","author":"Beck","year":"2009"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"issue":"10341","key":"10.1016\/j.vhri.2025.101091_bib28","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vhri.2025.101091_bib29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10620-021-06907-5","article-title":"Predictors of response to vedolizumab in patients with ulcerative colitis: results from the Greek VEDO-IBD cohort","volume":"67","author":"Bamias","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.vhri.2025.101091_bib30","series-title":"Upadacitinib for treating moderately to severely active ulcerative colitis TA856 Technology Appraisal Guidance","year":"2023"},{"key":"10.1016\/j.vhri.2025.101091_bib31","series-title":"Ustekinumab for treating moderately to severely active ulcerative colitis TA633 Technology Appraisal Guidance","year":"2020"},{"key":"10.1016\/j.vhri.2025.101091_bib32","series-title":"Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy TA329 Technology Appraisal Guidance","year":"2015"},{"key":"10.1016\/j.vhri.2025.101091_bib33","series-title":"Vedolizumab for treating moderately to severely active ulcerative colitis TA342 Technology Appraisal Guidance","year":"2020"},{"key":"10.1016\/j.vhri.2025.101091_bib34","series-title":"Tofacitinib for moderately to severely active ulcerative colitis TA547 Technology Appraisal Guidance","year":"2018"},{"key":"10.1016\/j.vhri.2025.101091_bib36","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using bayesian network meta-analysis","volume":"360","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.vhri.2025.101091_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8723949","article-title":"Colectomy rates for ulcerative colitis differ between ethnic groups: results from a 15-year nationwide cohort study","volume":"2016","author":"Misra","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.vhri.2025.101091_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/DCR.0000000000000978","article-title":"Incidence and long-term implications of Prepouch ileitis: an observational study","volume":"61","author":"Segal","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2025.101091_bib39","first-page":"S215","article-title":"P359 Risk factors for pouchitis after laparoscopic ileal-pouch-anal anastomosis in patients with ulcerative colitis","volume":"8","author":"Gonzalez","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ibd.20278","article-title":"Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis","volume":"14","author":"Ferrante","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.vhri.2025.101091_bib41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/DCR.0b013e3182417358","article-title":"The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis","volume":"55","author":"Suzuki","year":"2012","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.vhri.2025.101091_bib43","first-page":"A1","article-title":"The relation between disease activity, quality of life and health utility in patients with ulcerative colitis","author":"Woehl","year":"2008","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.vhri.2025.101091_bib44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cgh.2006.05.003","article-title":"Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?","volume":"4","author":"Arseneau","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.vhri.2025.101091_bib45","first-page":"1","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess (Winchester, England)"},{"issue":"5","key":"10.1016\/j.vhri.2025.101091_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2025.101091_bib48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MEG.0000000000001916","article-title":"Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece","volume":"33","author":"Vellopoulou","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib50","article-title":"On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data","volume":"11","author":"Cameron","year":"2018","journal-title":"a systematic review"},{"issue":"5","key":"10.1016\/j.vhri.2025.101091_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-effectiveness thresholds: the past, the present and the future","volume":"36","author":"Thokala","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.vhri.2025.101091_bib52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2025.101091_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.vhri.2023.02.006","article-title":"Does a standard cost-effectiveness threshold exist? The case of Greece","volume":"36","author":"Tzanetakos","year":"2023","journal-title":"Value Health Reg Issues"},{"issue":"12","key":"10.1016\/j.vhri.2025.101091_bib54","article-title":"EE478 a budget impact analysis of introducing filgotinib as a first-line treatment for moderate to severe ulcerative colitis in Greece","volume":"27","author":"Nomikos","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2025.101091_bib55","first-page":"769","volume":"83","author":"Taylor","year":"2024"},{"issue":"1","key":"10.1016\/j.vhri.2025.101091_bib56","first-page":"134","article-title":"Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia","volume":"27","author":"Al-Abdulkarim","year":"2024","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.vhri.2025.101091_bib57","article-title":"EE264 cost-effectiveness analysis of upadacitinib in patients with active non-radiographic axial spondyloarthritis in Greece","volume":"26","author":"Tzanetakos","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2025.101091_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.vhri.2025.101091_bib59","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","author":"Burr","year":"2021","journal-title":"Gut"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T03:06:17Z","timestamp":1742439977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":52,"alternative-id":["S2212109925000160"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101091","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101091"}}